Glenn Hunzinger, US Pharma & Life Science Leader for PricewaterhouseCoopers discusses the Pharmaceutical and life sciences deals insights: 2021 midyear outlook report. Hunzinger also talks about some trends in medtech M&A and the rise of the Special Purpose Acquisition Corporation mergers. Plus, MD+DI’s Omar Ford gives insight on Illumina’s controversial acquisition of Grail.
